Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 3, 1999, Pages 249-254

  Maier, Gary M ^a   Lockwood, G F ^a   Oppermann, J A ^a   Wei, G ^a   Bauer, P ^a   Fedler Kelly, J ^b   Grasela, T ^b  

^a Sanofi Research Division   (United States)

^b Pharmaceutical Outcomes Research   (United States)

Author keywords

Bioavailability; Bisphosphonates; Highly variable drugs; Population pharmacokinetics; Tiludronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; TILUDRONIC ACID;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; PLASMA;

EID: 0033379345     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190028     Document Type: Article

References (11)

1. Audran M., Clochon P., Ethgen D., Renier J.C., Rebel A., Basle MF. (1989) : Bone histomorphometric analysis in three Pagetic patients treated with a new bisphophonate SR 41319b. Presented at the XXI European Symposium on Calcified Tissues, Jerusalem, Israel.
2. Audran M., Clochon P., Etghen D., Mazieres B., Renier JC. (1989) : Treatment of Paget's disease of bone with (4-chlorophenyl) thiomethylene bisphosphonate. Clin. Rheumatol.,8: 71-79.
3. Fleisch H. (1991) : Bisphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944.
4. Unpublished data on file at Sanofi Recherche, Paris, France.
5. Report by the Bioequivalence Task Force (1988): Recommendations from the bioequivalence hearing conducted by the Food and Drug Administration, September 29 - October 1, 1986.
6. Blume H.H., Midha K.K. (1993) : Bio-International '92, conference on bioavailability,bioequivalence and pharmacokinetic studies. Eur. J. Drug Metab. Pharmacokinet., 18: 225-232.
7. Boeckmann A.J., Sheiner L.B., Beal S.L (1992) : NONMEM Users Guide - Part V. Introductory guide. NONMEM project group, University of California at San Francisco.
8. Kaniwa N., Aoyagi N., Ogata H., Ishii M. (1990) : Application of the NONMEM method to evaluation of the bioavailability of drug products. J. Pharm. Sci., 79: 1116-1120.
9. Pentikis H.S., Henderson J.D., Tran N.L., Ludden T.M. (1996) : Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm. Res., 13: 1116-1121.
10. Peck C. (1992) : Biopharmacuetics: old issues and new controversies. 31st International Industrial Pharmacy Conference, Austin, Texas.
11. Necciari J., Mougeot V., Pinfquier J.L., Laroix E., Arnoux P.H., Delauture D. (1992) : Influence of food intake (hypocalcic or normal meal) on the bioavailability of tiludronate. Presented at Vth World Conference on Clinical Pharmacology and Therapeutics; Yokohama, Japan.